|Bid||0.1050 x 686300|
|Ask||0.1100 x 26372000|
|Day's range||0.1050 - 0.1100|
|52-week range||0.0930 - 0.3000|
|Beta (5Y monthly)||1.48|
|PE ratio (TTM)||N/A|
|Earnings date||24 Aug 2021 - 30 Aug 2021|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||19 Sept 2005|
|1y target est||N/A|
AusCann Group Holdings Limited (ASX:AC8) ('AusCann' or 'the Company') is pleased to announce that it has submitted its first module to the Australian Pesticides and Veterinary Medicines Association (APVMA) to commence the submission of its dossier for the registration of DermaCann®, in development for anti-inflammatory and immune support in dogs with dermatological conditions.
AusCann Group Holdings Ltd (ASX:AC8), an Australian based pharmaceutical company focused on the development, production and distribution of cannabinoid-based medicines within Australia and internationally, is pleased to announce that it has entered into a scheme implementation deed (SID) with CannPal Animal Therapeutics Limited.
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...